|
7:05AM Alnylam Pharma and Roche advance RNAi therapeutic collaboration ...
In this phase of the collaboration, the partners will jointly collaborate on the discovery and development of specific RNAi therapeutic products and each will contribute key delivery technologies in the new disease target-focused effort. New delivery technologies include Alnylam lipid nanoparticles and Roche Madison dynamic polyconjugate delivery technologies. Is this the same type of therapy under MRNA development? If it is the same could this benefit MRNA in the form of a collaborative or licensing agreement? Rating :
 (1 Rating) |
51/Male |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
0.0177